StockNews.AI
PALI
StockNews.AI
9 hrs

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

1. Palisade Bio canceled its special stockholder meeting due to lack of quorum. 2. The meeting was originally scheduled for October 10, 2025. 3. Proposals for stockholders were withdrawn from consideration. 4. Palisade focuses on innovative therapies for autoimmune and inflammatory diseases. 5. The lack of quorum signals potential governance issues.

3m saved
Insight
Article

FAQ

Why Bearish?

The cancellation of the special meeting indicates potential governance problems. Historically, similar actions in biotech have led to declining investor confidence.

How important is it?

The cancellation reflects governance weaknesses, potentially affecting stockholder trust. Such issues are critical for a clinical-stage biotech, impacting stock performance.

Why Short Term?

Immediate investor sentiment may shift negatively due to governance concerns. Biotech companies often face volatility during such events.

Related Companies

IBBXBIVRTXREGN
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company determined to cancel its previously adjourned special meeting of stockholders (the “Special Meeting”), which had been scheduled to reconvene on Friday, October 10, 2025, at 10:00 a.m. Pacific Time. The Special Meeting was previously adjourned to, and reconvened on, September 26, 2025, but was adjourned again without any business being conducted, due to the lack of the required quorum as of the meeting time. As of today, the Company has still not received proxies that would constitute a quorum and has decided to cancel the Special Meeting and to withdraw from consideration by the Company’s stockholders the proposals set forth in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 18, 2025. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com. Investor Relations Contact JTC Team, LLCJenene Thomas908-824-0775PALI@jtcir.com 

Related News